



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Fabio Ciceri

SCIENTIFIC COUNCIL CHAIR WITH THE RESEARCH AND SCIENCES PORTFOLIO, ALWP
CHAIR, CONGRESS CO-PRESIDENT 2025

Italy





Donal McLornan

Scientific Council co-chair with the Research and Sciences portfolio, CMWP Chair
United Kingdom

Advancing Excellence in Research and Education

The EBMT continues to advance excellence in scientific research and education. This commitment is reflected both in our established face-to-face meetings, which remain essential for collaboration and scientific advancement, and in our expanding online educational initiatives, which enhance global accessibility and foster knowledge dissemination across the HCT and CT community.

In 2025, EBMT Working Parties (WPs) produced a significant number of high-impact publications. Participation in international scientific meetings has grown, alongside significant milestones that reinforce EBMT's leadership in HCT and CT.



Highlights of WP Scientific Activity from Outgoing Chairs

Acute Leukemia Working Party (ALWP)

The ALWP has contributed a substantial portfolio of research, with key studies including the selection of unrelated donors for allogeneic HCT with post-transplant cyclophosphamide in ALL, improved post-transplant outcomes in Ph+ ALL, survival outcomes of haploidentical versus matched unrelated donor transplantation in AML and donor selection strategies for elderly patients.

Cellular Therapy and Immunobiology Working Party (CTIWP)

The CTIWP continues its broad scientific initiatives addressing transplantation and CAR-T therapy outcomes. Current projects include CAR-T therapy in older patients, fertility preservation, immune monitoring, nutritional care, and real-world use of PTCy for graft-versus-host disease prophylaxis.

Chronic Malignancies Working Party (CMWP)

The CMWP has led international guidelines on the role of allo-HCT in “nonclassical” MPNs and MDS/MPNs, clinical-genomic profiling of MDS, and high-impact publications such as the application of machine learning to predict poor survival after HCT for myelofibrosis.

Landmark Publications

In 2025, EBMT published the updated practice recommendations: “[*Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours, and immune disorders: 2025 EBMT practice recommendations*](#)” (Greco et al., *Bone Marrow Transplantation*, 2025). These recommendations offer essential guidance for clinicians and researchers in HCT and CT.

The 2024 EBMT Activity Report, “*Crossing One Million HCTs and 20,000 CAR-T – A Landmark in Cellular Therapy*,” will be available open-access. Published annually for over 35 years, the report remains a key resource for global trends, therapeutic advancements and country-level contributions in transplantation, CAR-T, and gene therapy.

Registry Milestones and Data Harmonisation

By February 2026, the EBMT registry had recorded over 17,500 patients treated with CAR-T therapies, reflecting the rapidly expanding role of cellular therapy. EBMT remains committed to data quality and harmonisation, with forthcoming guidelines

on reporting lines of treatment to be published in *Bone Marrow Transplantation*.

Practice Harmonisation and Guidelines

The Practice Harmonisation and Guidelines Committee held its third annual workshop in September, uniting WPs, the EBMT Nurses Group, and a joint EBMT-ISCT initiative. The 14 workshops are expected to generate over 15 new EBMT recommendations, complementing 14 publications from previous editions.

Advancing Translational Science

EBMT is strengthening the integration of basic, fundamental, and translational research across cellular and gene therapy initiatives. Key efforts will include expanded grant opportunities, enhanced bioinformatics support, and alignment of scientific priorities, as outlined in [“Advancing the Integration of Basic and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress”](#) (McLornan et al., *Bone Marrow Transplantation*, 2025).

Education and Future Directions

The EBMT Educational Programme continues to disseminate knowledge and promote best practices in HCT and CT. The Educational Task Force is developing a global portfolio of resources, including an online library, e-learning initiatives, a core curriculum, and the EBMT examination.

Looking Ahead

EBMT continues to build momentum across research, education, and clinical practice. We anticipate many new initiatives in 2026 and look forward to the 52nd Annual Meeting of the EBMT in Madrid to celebrate achievements and further advance transplantation and cellular therapy worldwide.